Acer Therapeutics Inc. (NASDAQ: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, according to the company’s website (see here: www.acertx.com). SNNLive spoke with Chris Schelling, CEO and Founder of Acer Therapeutics Inc. (NASDAQ: ACER), via Zoom to discuss the following topics:
- 0:45 Acer Therapeutics' COVID-19 Drug Development Program
- 3:23 Talking with FDA to move program right to Phase 2/3 study
- 5:30 Acer's focus on using reformulated assets for COVID-19 indication
- 6:17 Next steps with the FDA to move COVID-19 program forward
- 7:00 History of Acer Therapeutics
- 10:06 Corporate strategy on finding new indications for reformulated assets
- 14:03 Chris Schelling's background prior to founding Acer
- 15:15 Vision for ACER in 2020 and beyond
For more information about Acer Therapeutics Inc. please visit: www.acertx.com
The interview may contain forward looking statements about Acer Therapeutics Inc. See Acer Therapeutics Inc.’s periodic filings with the Securities and Exchange Commission for more complete information.
Please read our full disclosure here.